Effect of long-term prophylactic treatment on survival after myocardial infarction.
Survivors of the acute phase of a myocardial infarction still have an increased risk of dying, primarily due to causes directly attributable to their coronary heart disease. This review of randomized clinical trials of various interventions with the potential to prolong life in these patients is an attempt to answer a vitally important question. What, if anything, can be done to improve the long-term prognosis in patients who have survived the initial one or two weeks after suffering an acute myocardial infarction? Seven classes of intervention are considered: anticoagulants, platelet-active drugs, lipid-lowering regimens, antiarrhythmic agents, physical exercise, calcium antagonists and beta-blockers. So far only beta-blockers have been shown to have a favorable effect on long-term survival. Many of the trials reviewed had design limitations; in particular, the sample size was often too small for the results to be conclusive.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005081:Exercise Therapy; D005500:Follow-Up Studies; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D011897:Random Allocation
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents